U.S. FDA flags probable cancer-causing impurity in common heartburn drugs

(Reuters) – The U.S. Food and Drug Administration said on Friday that some medicines containing ranitidine, including Sanofi SA’s Zantac, had traces of a probable cancer-causing impurity called N-nitrosodimethylamine (NDMA) at low levels. The European Medicines Agency said it will also start a review of the over-the-counter heartburn drug. (bit.ly/2masHyV) The FDA has been investigating NDMA and other nitrosamine impurities in blood pressure and heart failure medicines called Angiotensin II Receptor Blockers (ARBs) since last year. ARBs such as valsartan, the generic version of Novartis AG’s Diovan, have been recalled by drugmakers such as Mylan NV, Teva Pharmaceutical Industries and Novartis’ Sandoz, as the drugs have been found to contain probable carcinogens.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s